Vir Biotechnology Reports Q2 2026 Financial Results

What Happened
Vir Biotechnology, Inc. filed a Form 8-K on August 5, 2026 to announce its financial results for the quarter ended June 30, 2026 (Q2 2026). The company furnished a press release dated August 5, 2026 as Exhibit 99.1, which is incorporated by reference in the filing. The report was signed by Marianne De Backer, President and Chief Executive Officer.

Key Details

• Filing date: August 5, 2026.
• Reporting period: quarter ended June 30, 2026 (Q2 2026).
• Press release: furnished as Exhibit 99.1 to the Form 8-K.
• Form signed by Marianne De Backer, CEO.

Why It Matters
This 8-K signals that Vir has publicly released its latest quarterly results; investors should review the furnished press release (Exhibit 99.1) for the company’s reported revenues, expenses, net income or loss, cash balance, and any management commentary or guidance. The Form 8-K itself does not detail financial figures, so the press release and any accompanying financial statements or investor materials are the sources for the specific metrics that may affect valuation and near-term trading.